Accretion Pharmaceuticals P/B Ratio
Current P/B Ratio
2.7
Moderate Valuation
High - Premium to book value, growth expectations or asset-light model
Accretion Pharmaceuticals (ACCPL) P/B ratio is 2.7 (Moderate), book value per share ₹18.75 vs Healthcare average P/B of -0.95 — High - Premium to book value, growth expectations or asset-light model. Compare with ACCPL fundamental valuation to assess whether the stock is under or overvalued.
Current Valuation Metrics
P/B Ratio
2.7
Current Price
₹
Book Value/Share
₹18.75
Exchange
None
Book Value Breakdown (2025)
Balance Sheet Components
Total Equity
₹15 Cr
Share Capital
₹8 Cr
Reserves & Surplus
₹7 Cr
Outstanding Shares
8,000,000
Book Value per Share
₹18.75
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
-0.95
Sector Median
0.62
Sector Rank
#11 of 50
Sector Percentile
22.0%
ACCPL P/B Ratio — Valuation Insights & Book Value Analysis
Accretion Pharmaceuticals price-to-book ratio interpretation, valuation status and historical context — current P/B 2.7 (Moderate). View ACCPL 52-week performance for the annual high/low range and current price position.
- Trading at premium to sector average PB of -0.95
ACCPL vs Healthcare Peers — P/B Ratio Comparison
Accretion Pharmaceuticals P/B 2.7 vs Healthcare average -0.95, median 0.62 — range -34.67–1.04.
Sector Average
-0.95
Sector Median
0.62
Lowest P/B
-34.67
Highest P/B
1.04
Companies
50
| Company | Symbol | P/B Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Rekvina Laboratories | VINRKLB | -34.67 | ₹26 | Low |
| Sun Pharma Advanced Rese… | SPARC | -13.45 | ₹4,533 | Low |
| Span Divergent | SDL | -6.32 | ₹19 | Low |
| Oxygenta Pharmaceutical | OXYGENTAPH | -5.54 | ₹203 | Low |
| Satiate Agri | SATAGRI | -3.39 | ₹8 | Low |
| Adline Chem Lab | ADLINE | -3.03 | ₹5 | Low |
| Bharat Immunologicals | BIBCL | -2.29 | ₹76 | Low |
| Parmax Pharma | PARMAX | -2.19 | ₹12 | Low |
| Krebs Biochemicals & Ind… | KREBSBIO | -0.81 | ₹128 | Low |
| Cresanto Global | CRESANTO | -0.7 | ₹2 | Low |